Why Dissolution and Permeability Must Be Studied Separately

Dissolution and permeability describe separate stages in peptide-delivery research. Dissolution concerns whether peptide-containing material enters a surrounding liquid phase, while permeability concerns whether a measurable peptide fraction moves across a membrane, cell layer, tissue, or other experimental barrier. A formulation may produce rapid dissolution with limited transport, or slower dissolution with a different local transport profile. Combining these measurements into one general statement can obscure where a formulation succeeds, changes, or stops progressing through the experimental sequence.

This distinction is central to research into future oral peptide-delivery systems. Peptide release, dissolution, structural stability, mucus movement, and epithelial transport must be measured as connected but separate questions.

This article is provided for general educational purposes and explains formulation, delivery, and research concepts associated with oral peptide delivery. It does not establish the regulatory status of any specific InStrips product or determine whether a particular product is appropriate for any person.

A high dissolution percentage does not establish peptide permeability, and increased transport across a laboratory model does not establish that a complete dosage form releases the peptide consistently under gastrointestinal conditions.

What Is Dissolution?

Dissolution is the process through which a substance moves from a solid, semi-solid, particulate, or associated state into a surrounding liquid phase.

In peptide-formulation research, dissolution testing may examine:

• how quickly peptide-containing material enters the medium
• what fraction becomes dissolved
• whether release continues over time
• whether precipitation follows initial dissolution
• whether the intact peptide remains measurable
• how pH or fluid composition changes the result

Dissolution does not describe movement across an epithelial barrier.

What Is Permeability?

Permeability describes movement of a measured substance across a defined barrier.

Experimental barriers may include:

• artificial membranes
• cell monolayers
• mucus-covered cell systems
• isolated intestinal tissue
• engineered tissue models
• intestinal segments in animal research

Permeability measurements depend on the barrier model, peptide concentration, exposure period, sampling method, and analytical recovery.

Why the Terms Are Sometimes Blurred

Dissolution and permeability are both involved in the sequence leading from a dosage form to a transport measurement.

This can lead to broad descriptions such as improved delivery even when only one stage was measured.

For example, a study may report:

• faster peptide release from a tablet
• greater peptide solubility in a formulation
• greater transport across a cell model
• greater measured exposure in an animal experiment

These are different findings and should not be treated as interchangeable.

Disintegration Comes Before Dissolution in Many Solid Forms

A tablet or capsule may first open, erode, swell, or break into smaller units.

Disintegration may increase the material exposed to fluid, but the peptide may remain:

• inside granules
• adsorbed to particles
• associated with polymers
• contained within lipid structures
• present as an undissolved complex

Physical breakup must therefore be distinguished from peptide dissolution.

Release and Dissolution Are Also Distinct

A peptide can leave a dosage-form matrix without becoming molecularly dissolved.

Released material may include:

• particles
• aggregates
• colloids
• lipid droplets
• polymer-peptide complexes
• precipitated ion pairs

A total-release measurement should not automatically be described as dissolved peptide unless the analytical method separates these fractions.

Dissolved Peptide May Not Remain Intact

A peptide may dissolve and then undergo chemical, physical, or enzymatic change.

Possible changes include:

• fragmentation
• oxidation
• deamidation
• aggregation
• conformational change
• adsorption to test equipment

A dissolution assay should determine whether it measures intact peptide, total peptide-related material, or a nonspecific signal.

Permeability Requires an Available Peptide Fraction

Only the fraction present and available near the experimental barrier can contribute to a transport measurement.

A peptide may be present in the donor compartment while remaining:

• bound to a polymer
• retained in a lipid droplet
• associated with a counterion
• aggregated
• adsorbed to the test vessel
• trapped in mucus

Total donor concentration may therefore differ from the concentration available at the barrier surface.

High Dissolution with Low Permeability

A peptide may dissolve readily in the donor medium but show limited transport across an experimental barrier.

Possible reasons include:

• large molecular size
• hydrophilicity
• multiple charged groups
• limited transcellular partitioning
• restricted paracellular movement
• interaction with mucus
• degradation near the barrier

Improving dissolution alone may not change these properties.

Low Dissolution with Apparent Permeability

In some systems, a small dissolved fraction may produce a measurable transport signal even though much of the peptide remains associated with the formulation.

This can occur when:

• the peptide is concentrated near the barrier
• release occurs gradually
• a formulation adheres to the test surface
• the analytical method detects a low transported quantity
• the barrier model has comparatively high permeability

The transport result should be reported together with the dissolved and released fractions.

Solubility and Dissolution Are Not Identical

Solubility describes the quantity that can remain dissolved under defined equilibrium or near-equilibrium conditions.

Dissolution rate describes how quickly material enters the dissolved state.

A peptide-associated material may have:

• high apparent solubility but slow dissolution
• low equilibrium solubility but rapid initial dissolution
• temporary supersaturation followed by precipitation
• different solubility at different pH values

Both the amount and the time course can affect what reaches a permeability model.

Supersaturation and Precipitation

Some formulations temporarily maintain more peptide-associated material in solution than would remain dissolved at equilibrium.

This condition may change through:

• dilution
• pH transition
• loss of cosolvent
• ion exchange
• temperature change
• interaction with salts or bile materials

An early dissolution sample may therefore show a higher concentration than samples collected later.

Peptide Charge and pH

Peptide charge can change with pH because peptides contain ionizable groups.

Changing charge may influence:

• solubility
• aggregation
• polymer binding
• mucus interaction
• membrane association
• analytical recovery

A pH change can improve one measurement while reducing another.

Dissolution Media

Dissolution studies may use water, buffers, simulated gastric fluid, simulated intestinal fluid, or more complex biorelevant media.

Media differ in:

• pH
• buffer capacity
• ionic strength
• enzymes
• bile materials
• phospholipids
• surface tension

A dissolution result obtained in purified water may not describe behavior in a medium containing salts, enzymes, or bile-related components.

Sink Conditions

Sink conditions are intended to keep the surrounding medium capable of dissolving additional material throughout the experiment.

When sink conditions are not maintained:

• dissolution may slow
• precipitation may occur
• concentration gradients may change
• release may appear incomplete
• formulations may be difficult to compare

Highly favorable sink conditions can also differ substantially from the limited and changing fluid conditions represented in gastrointestinal research.

Agitation and Fluid Movement

Dissolution apparatus commonly uses controlled movement to mix the medium and dosage form.

Agitation can affect:

• boundary-layer thickness
• tablet erosion
• particle dispersion
• coating opening
• precipitation
• sampling uniformity

A release profile measured at one agitation rate may differ at another rate.

Permeability Models

Permeability models range from simplified artificial membranes to living cell or tissue systems.

Each model may represent different features:

• passive diffusion
• paracellular pathways
• transcellular pathways
• transport proteins
• mucus
• metabolic activity
• barrier recovery

Results from one model should not be assumed to represent another model with a different barrier structure.

Artificial Membranes

Artificial membrane systems can provide controlled comparisons of passive partitioning or diffusion.

They generally do not reproduce every feature of intestinal tissue, such as:

• tight junctions
• living-cell responses
• active transport
• metabolism
• mucus renewal
• barrier recovery

They can support early screening but cannot answer every peptide-transport question.

Cell Monolayers

Cell monolayers are commonly used to examine movement across an epithelial-like barrier.

Measurements may include:

• peptide concentration in the receiving compartment
• apparent permeability coefficients
• electrical resistance
• marker-compound movement
• cell viability
• microscopic observations

Transport results require controls showing whether the barrier remained intact during the experiment.

Isolated Tissue

Isolated tissue can preserve more structural complexity than a cell monolayer, but its properties may change after removal and during incubation.

Interpretation may depend on:

• tissue region
• tissue orientation
• viability period
• oxygenation
• temperature
• surface area
• sampling method

A permeability value should identify the tissue and experimental setup rather than being treated as a universal property.

Mucus Can Separate Dissolution from Permeability

A peptide can be dissolved in the bulk donor medium while failing to reach the epithelial surface because of mucus interaction.

The formulation may:

• bind to mucin
• aggregate within mucus
• diffuse slowly
• remain near the luminal surface
• alter mucus structure

A model without mucus may therefore produce different transport measurements from a mucus-containing model.

Permeation Enhancers

Some formulation components are investigated for their ability to change transport across an experimental barrier.

Interpretation should include:

• enhancer concentration
• exposure time
• peptide concentration
• barrier-integrity measurements
• cell-viability measurements
• recovery after removal

Greater transport accompanied by substantial loss of barrier integrity should not be described as controlled permeability.

Enzyme-Related Components

A formulation may include materials intended to alter peptide degradation in a dissolution or permeability experiment.

Their effects can differ according to:

• enzyme type
• concentration
• pH
• incubation time
• peptide sequence
• formulation composition

Preserving more intact peptide in the donor compartment may change the quantity available for permeability measurement, but the two results remain analytically distinct.

Donor Concentration

Permeability calculations depend on the peptide concentration available in the donor compartment.

If the peptide precipitates, degrades, binds to the formulation, or adsorbs to the apparatus, the nominal concentration may differ from the measured available concentration.

Researchers may therefore need to measure:

• total donor peptide
• dissolved intact peptide
• unbound peptide
• remaining formulation-associated peptide
• degradation products

Receiver-Side Measurements

The amount detected in the receiver compartment may be small relative to the donor quantity.

Reliable interpretation requires attention to:

• analytical sensitivity
• background signal
• sample stability
• adsorption to plates or tubing
• mass balance
• peptide degradation after transport

A signal near the analytical detection limit requires appropriate controls and replication.

Mass Balance

Mass-balance analysis attempts to account for peptide across the complete experimental system.

Researchers may measure peptide:

• remaining in the dosage form
• present in the donor medium
• associated with the barrier
• present in the receiver medium
• adsorbed to equipment
• present as degradation products

Low recovery can indicate degradation, adsorption, extraction loss, or an incomplete analytical method.

Time Scales May Differ

Dissolution and permeability can occur over different time scales.

A dosage form may release peptide over several hours, while a cell model may remain suitable for a shorter experimental period.

This mismatch may require:

• staged sampling
• transfer of dissolution samples
• combined dissolution-permeability systems
• separate model validation
• careful interpretation of exposure duration

Using a short permeability experiment cannot describe a longer release process without additional assumptions.

Combined Dissolution-Permeability Systems

Integrated systems can connect a dissolution compartment with a receiving barrier model.

These systems may help examine the sequence from dosage-form release to transport, but the measurements should still be reported separately.

Researchers may need to distinguish:

• peptide released from the dosage form
• peptide dissolved in the donor phase
• peptide reaching the barrier
• peptide associated with the barrier
• peptide appearing in the receiver phase

Why One Percentage Is Not Enough

A single delivery percentage may combine several losses and processes without identifying where they occurred.

Separate percentages may be needed for:

• dosage-form release
• intact-peptide dissolution
• stability during incubation
• movement through mucus
• barrier transport
• analytical recovery

This separation allows formulation changes to be linked to the stage they actually affect.

Published Research on Gastrointestinal Permeability

A review available through the National Library of Medicine examines gastrointestinal permeation enhancers and the experimental factors used to assess epithelial transport. It discusses the importance of mechanism, concentration, barrier effects, and model selection when interpreting permeability findings.

Permeability research of this kind addresses a different question from whether a solid or dispersed formulation releases and dissolves its peptide payload.

Solid Dosage Forms Add Another Stage

When the peptide is contained in a tablet, capsule, pellet, or matrix, the formulation must first interact with fluid before dissolution and permeability can be studied.

The sequence described in how solid dosage forms affect peptide release shows why tablet opening or matrix erosion should not be combined with later transport measurements.

What Dissolution Testing May Establish

Dissolution testing may establish:

• how quickly peptide-related material enters a liquid phase
• what fraction is measurable over time
• whether precipitation occurs
• how media and pH affect the profile
• whether intact peptide remains detectable

What Permeability Testing May Establish

Permeability testing may establish:

• whether peptide crosses a selected barrier model
• the measured rate of movement
• how formulation components change transport
• whether barrier properties change during exposure
• whether measured changes are reversible in the model

What Neither Test Establishes Alone

Neither dissolution nor permeability testing alone establishes:

• complete performance of a finished dosage form
• peptide stability throughout gastrointestinal transit
• reproducible measured exposure under other conditions
• equivalence among formulations
• findings after repeated long-duration testing
• performance outside the selected model

Final Perspective

Dissolution and permeability are connected but distinct research measurements.

Dissolution determines whether peptide-containing material becomes available in a liquid phase. Permeability determines whether an available peptide fraction moves across a selected experimental barrier.

Accurate evaluation should report dosage-form disintegration, peptide release, intact-peptide dissolution, precipitation, donor availability, barrier integrity, transport, mass balance, and analytical recovery separately rather than combining all stages into one general statement about peptide delivery.